EnVVeno Medical Ownership
| NVNO Stock | USD 4.91 0.09 1.80% |
Shares in Circulation | First Issued 2016-09-30 | Previous Quarter 13.3 M | Current Value 16.1 M | Avarage Shares Outstanding 4.9 M | Quarterly Volatility 5.3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
EnVVeno |
EnVVeno Stock Ownership Analysis
About 30.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.44. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. enVVeno Medical Corp recorded a loss per share of 1.65. The entity last dividend was issued on the 30th of November 2020. The firm had 1:25 split on the 30th of November 2020. enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California. Envveno Medical operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 24 people. To find out more about enVVeno Medical Corp contact Robert Berman at 949 261 2900 or learn more at https://www.envveno.com.Besides selling stocks to institutional investors, EnVVeno Medical also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different EnVVeno Medical's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align EnVVeno Medical's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
EnVVeno Medical Quarterly Liabilities And Stockholders Equity |
|
EnVVeno Medical Insider Trades History
Less than 1% of enVVeno Medical Corp are currently held by insiders. Unlike EnVVeno Medical's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against EnVVeno Medical's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of EnVVeno Medical's insider trades
EnVVeno Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as EnVVeno Medical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading enVVeno Medical Corp backward and forwards among themselves. EnVVeno Medical's institutional investor refers to the entity that pools money to purchase EnVVeno Medical's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Blackrock Inc | 2023-12-31 | 38.1 K | Northern Trust Corp | 2023-12-31 | 37.5 K | State Street Corporation | 2023-12-31 | 26.6 K | Fermata Advisors, Llc | 2024-03-31 | 23.2 K | Susquehanna International Group, Llp | 2023-12-31 | 18.7 K | Dimensional Fund Advisors, Inc. | 2023-12-31 | 18.3 K | Marshall Wace Asset Management Ltd | 2023-12-31 | 15.3 K | Arthur M. Cohen & Associates Llc | 2023-12-31 | 14 K | Tamar Securities, Llc | 2023-12-31 | 14 K | Nantahala Capital Management, Llc | 2023-12-31 | 1.4 M | Kingdon Capital Management Llc | 2023-12-31 | 838.4 K |
enVVeno Medical Corp Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific EnVVeno Medical insiders, such as employees or executives, is commonly permitted as long as it does not rely on EnVVeno Medical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases EnVVeno Medical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Biodyne Holding, S.a. over two weeks ago Disposition of 75000 shares by Biodyne Holding, S.a. of EnVVeno Medical at 0.38 subject to Rule 16b-3 | ||
Hamed Alavi over a month ago Disposition of 8334 shares by Hamed Alavi of EnVVeno Medical at 3.59 subject to Rule 16b-3 | ||
Gray Robert over a month ago Acquisition by Gray Robert of 7211 shares of EnVVeno Medical at 6.7 subject to Rule 16b-3 | ||
Biodyne Holding, S.a. over a month ago Disposition of 100000 shares by Biodyne Holding, S.a. of EnVVeno Medical at 0.4 subject to Rule 16b-3 | ||
Jenusaitis Matthew over a month ago Disposition of 1041 shares by Jenusaitis Matthew of EnVVeno Medical subject to Rule 16b-3 | ||
Hamed Alavi over two months ago Disposition of 8334 shares by Hamed Alavi of EnVVeno Medical at 6.22 subject to Rule 16b-3 | ||
Duhay Francis over three months ago Acquisition by Duhay Francis of 13856 shares of EnVVeno Medical subject to Rule 16b-3 | ||
Biodyne Holding Sa over six months ago Sale by Biodyne Holding Sa of 150000 shares of EnVVeno Medical |
EnVVeno Medical Corporate Filings
| 10th of May 2024 Other Reports | ViewVerify | |
10Q | 8th of May 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 24th of April 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 15th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in enVVeno Medical Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for EnVVeno Stock analysis
When running EnVVeno Medical's price analysis, check to measure EnVVeno Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EnVVeno Medical is operating at the current time. Most of EnVVeno Medical's value examination focuses on studying past and present price action to predict the probability of EnVVeno Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EnVVeno Medical's price. Additionally, you may evaluate how the addition of EnVVeno Medical to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Stocks Directory Find actively traded stocks across global markets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
Is EnVVeno Medical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of EnVVeno Medical. If investors know EnVVeno will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about EnVVeno Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.65) | Return On Assets (0.37) | Return On Equity (0.58) |
The market value of enVVeno Medical Corp is measured differently than its book value, which is the value of EnVVeno that is recorded on the company's balance sheet. Investors also form their own opinion of EnVVeno Medical's value that differs from its market value or its book value, called intrinsic value, which is EnVVeno Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because EnVVeno Medical's market value can be influenced by many factors that don't directly affect EnVVeno Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between EnVVeno Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if EnVVeno Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, EnVVeno Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.